Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-11

Clinical Trial Update: Triumeq in Amyotrophic Lateral Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial of Triumeq for amyotrophic lateral sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: Macquarie University, Australia | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: TERMINATED